#324 Gvoke Glucagon

Liquid Glucagon

Scott Benner introduces Gvoke, the world's first liquid stable glucagon, highlighting its ease of use and readiness for emergency situations. Paul Edick explains that Gvoke is prefilled, premixed, and premeasured, eliminating the need for refrigeration, making it a revolutionary tool for managing hypoglycemia in both adults and children with diabetes 1. Paul shares the potential for Gvoke to be used beyond emergency scenarios, such as in closed-loop systems that require both insulin and glucagon 2.

We will have the only liquid stable glucagon. So if there's a system that works, what you now have, not to take too much time, but what you now have is the real innovation here is a liquid stable glucagon.

--- Paul Edick

This innovation opens up possibilities for more integrated diabetes management systems 3.

   

Drug Formulation

Paul describes the innovative approach behind Gvoke's formulation, which transforms unstable compounds into stable, liquid forms. This technology not only benefits diabetes management but also has potential applications in other therapeutic areas 4. The process involves creating liquid stable products from drugs that are traditionally unstable in solution, offering a more convenient and reliable option for patients.

What I found was fascinating, very simple, yet elegant technology in terms of formulating, taking old drugs that are not stable in solution, and formulating them into liquid stable products that are way more useful for patients in many different therapeutic areas.

--- Paul Edick

Paul's vision for the company includes expanding this technology to address various medical needs beyond diabetes 4.

   

Future Uses

The future of glucagon use is promising, with ongoing research into its application in new therapeutic areas. Paul discusses studies on continuous infusion of glucagon for individuals who do not recognize hypoglycemia symptoms, as well as its potential use in post-bariatric surgery patients to prevent severe hypoglycemia 5. The exploration of mini-dosing and other innovative uses of glucagon could significantly enhance diabetes care.

We're studying our glucagon in continuous infusion for people who don't recognize their hypoglycemia symptoms. That's the classic person who is 1 minute just fine the next minute in a car accident.

--- Paul Edick

These advancements aim to provide more comprehensive solutions for managing diabetes and related conditions 6.